For Healthcare Professionals

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma


About the study

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Relapsed or refractory multiple myeloma (MM) and must:

  1. have documented disease progression during or after their last myeloma therapy
  2. be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM
  3. Must have measurable disease
  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  5. Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP)


Exclusion Criteria:

  1. Known active or history of central nervous system (CNS) involvement of MM
  2. Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis.
  3. Impaired cardiac function or clinically significant cardiac disease
  4. Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)
  5. For Part 1: received prior therapy with CC-92480
  6. For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
  7. Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment

Received any of the following within 14 days prior to initiating study treatment:

  1. Plasmapheresis
  2. Major surgery
  3. Radiation therapy other than local therapy for myeloma associated bone lesions
  4. Use of any systemic anti-myeloma drug therapy
  5. Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment
  6. COVID-19 vaccine within 14 days prior to C1D1

Other protocol-defined inclusion/exclusion criteria apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Multiple Myeloma

Age (in years)



Phase 1/Phase 2

Participants needed


Est. Completion Date

Oct 12, 2026

Treatment type



Bristol-Myers Squibb identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.